Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2013-11, Vol.27 (11), p.2253-2254
Hauptverfasser:	Nieborowska-Skorska, M, Hoser, G, Hochhaus, A, Stoklosa, T, Skorski, T
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/737 631/67/1059/2326 692/699/67/1990/283/1896 692/700/459 Animals Antineoplastic Agents - adverse effects Antioxidants Antioxidants - therapeutic use Benzamides - adverse effects Cancer Cancer Research Chronic myeloid leukemia Cloning Critical Care Medicine Cytokines Cytotoxicity DNA damage Drug Resistance, Neoplasm - drug effects Fusion Proteins, bcr-abl - genetics Gene mutations Genetic aspects Hematology Humans Identification and classification Imatinib Imatinib Mesylate Intensive Interleukin Receptor Common gamma Subunit - physiology Internal Medicine Kinases letter-to-the-editor Letters to the editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - prevention & control Medicine Medicine & Public Health Mice Mice, Inbred NOD Mice, SCID Mutation Mutation - genetics Oncology Oxidants Oxidizing agents Phosphotransferases Piperazines - adverse effects Properties Pyrimidines - adverse effects Stem cells Testing Vitamin E Vitamin E - therapeutic use Xenografts Xenotransplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!